NASDAQ$EXAS
Exact Sciences Corp · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported record revenue and anticipated continued growth in 2023.
Exact Sciences reported a 17% increase in total revenue for Q4 2022, reaching $553 million. Screening revenue was $404 million and Precision Oncology revenue was $143 million. The company anticipates revenue of $2,265-$2,315 million and positive adjusted EBITDA for full year 2023.
- Total fourth quarter revenue was $553 million, an increase of 17% or 28% excluding COVID-19 testing.
- Screening revenue was $404 million and Precision Oncology revenue was $143 million.
- Gross margin including amortization of acquired intangible assets was 70 percent, and non-GAAP gross margin excluding amortization of acquired intangible assets was 73 percent.
- Net loss was $127.7 million, or $0.72 per share.
Headline financials
Revenue & EPS history
Exact Sciences · Revenue · Quarterly
$553M
Revenue by segment
Exact Sciences · $547M total across 2 segments · Q4 2022
- Screening$404M+45.3%73.8%
- Precision Oncology$143M-3.8%26.2%
Forward guidance
The company anticipates revenue of $2,265-$2,315 million during 2023.
Tailwinds
- Screening revenue of $1,660-$1,690 million
- Precision Oncology revenue of $600-$620 million
- COVID-19 testing revenue of $5 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2022
+0.8%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+3.4%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+35.0%
Q2 2016
Best reaction
-27.1%
Q3 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q4 2025 | +0.0% | +0.0% | +0.7% | |
| Q3 2025 | +3.8% | -1.2% | +51.0% | |
| Q2 2025 | -8.2% | -11.0% | +14.7% | |
| Q1 2025 | +9.1% | +13.0% | +19.3% | |
| Q4 2024 | -1.9% | -0.6% | -9.6% | |
| Q3 2024 | -23.1% | -27.6% | -12.0% | |
| Q2 2024 | +24.3% | +19.7% | +32.4% | |
| Q1 2024 | -11.8% | -9.5% | -30.1% | |
| Q4 2023 | -5.2% | -8.3% | -1.0% | |
| Q3 2023 | +1.4% | +5.9% | +8.8% | |
| Q2 2023 | -12.7% | -12.6% | -14.2% | |
| Q1 2023 | +14.9% | +15.5% | +32.2% | |
| Q4 2022 | +1.9% | -5.4% | +3.0% | |
| Q3 2022 | +13.8% | +23.9% | +40.4% | |
| Q2 2022 | +0.8% | -0.3% | -23.2% | |
| Q1 2022 | -0.2% | -12.1% | -20.4% | |
| Q4 2021 | -6.9% | +5.7% | -9.5% | |
| Q3 2021 | -3.2% | +3.3% | -17.3% | |
| Q2 2021 | -0.0% | -3.2% | -7.2% | |
| Q1 2021 | -11.9% | -16.8% | -14.0% | |
| Q4 2020 | -9.0% | -4.6% | -17.4% | |
| Q3 2020 | +19.7% | +16.2% | +8.7% | |
| Q2 2020 | +0.1% | -1.8% | -22.7% | |
| Q1 2020 | +6.3% | +7.7% | +11.3% | |
| Q4 2019 | -1.1% | +1.4% | -46.8% | |
| Q3 2019 | -9.5% | -3.1% | -12.2% | |
| Q2 2019 | -0.0% | -2.4% | +1.9% | |
| Q1 2019 | -0.9% | +6.7% | +3.5% | |
| Q4 2018 | +10.1% | +10.7% | +6.4% | |
| Q3 2018 | +15.5% | +20.7% | +23.3% | |
| Q2 2018 | -11.7% | -12.9% | +28.1% | |
| Q1 2018 | +14.9% | +10.5% | +14.5% | |
| Q4 2017 | -9.2% | -4.9% | -5.4% | |
| Q3 2017 | +7.5% | +10.8% | +13.0% | |
| Q2 2017 | +0.5% | +0.1% | +4.2% | |
| Q1 2017 | +26.1% | +30.1% | +40.0% | |
| Q4 2016 | +14.0% | +7.6% | +2.9% | |
| Q3 2016 | -22.1% | -20.5% | -19.3% | |
| Q2 2016 | +35.0% | +39.5% | +52.9% | |
| Q1 2016 | -16.9% | — | — | |
| Q4 2015 | -9.5% | — | — | |
| Q3 2015 | +1.0% | — | — | |
| Q2 2015 | -8.9% | — | — | |
| Q1 2015 | +6.2% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +6.1% | — | — | |
| Q2 2014 | +1.1% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | +10.5% | — | — | |
| Q3 2013 | -1.0% | — | — | |
| Q2 2013 | -8.0% | — | — | |
| Q1 2013 | +2.4% | — | — | |
| Q4 2012 | +2.7% | — | — | |
| Q3 2012 | +5.4% | — | — | |
| Q2 2012 | +5.4% | — | — | |
| Q1 2012 | +1.4% | — | — | |
| Q4 2011 | +4.6% | — | — | |
| Q3 2011 | -4.1% | — | — | |
| Q2 2011 | -6.7% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q4 2010 | +2.8% | — | — | |
| Q3 2010 | -27.1% | — | — | |
| Q2 2010 | +3.3% | — | — | |
| Q1 2010 | +6.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro